An Osaka Metropolitan University-led team evaluated the effects of SGLT2 inhibitors in protecting the kidneys, showing that ...
Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback